Strides Pharma Science Singapore arm gets USFDA nod for Major Depressive Disorder drug Fluoxetine

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly.

Fluoxetine tablets has a market size of ~US$ 23.9 Mn as per IMS.

"This approval further strengthens the Company's presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine capsules, which has a marketsize of US$106 Mn," the Company stated.

Read also: Strides gets USFDA nod for Generic Suprep Bowel Prep Kit

The Fluoxetine tablets will be manufactured at the company’sfacility in Puducherry. The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 245 ANDAs have been approved.

The company has set a target to launch ~ 60 new products over three years in the US, as per the release.

Read also: Strides Pharma Science Singapore arm gets USFDA okay for fibromyalgia drug Pregabalin

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor‐ funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). 

Read also: Strides Pharma Science arm secures USFDA nod for Gabapentin tablets for neuropathic pain treatment